Bioequivalency Study of Meloxicam Tablets Under Fed Conditions
Information source: Roxane Laboratories
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Inflammation
Intervention: Meloxicam (Drug)
Sponsored by: Roxane Laboratories
Official(s) and/or principal investigator(s):
Soran Hong, MD, Principal Investigator, Affiliation: Novum Pharmaceutical Research Services
The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam
tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fed conditions using a
single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
Official title: A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of 15 mg Meloxicam Tablets Under Fed Conditions
Study design: Treatment, Randomized, Open Label, Crossover Assignment, Bio-equivalence Study
Primary outcome: Bioequivalence
Minimum age: 18 Years.
Maximum age: 45 Years.
- No clinically significant abnormal findings on the physical examination, medical
history, or clinical laboratory results during screening.
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to Meloxicam or any comparable or similar
Locations and Contacts
Novum Pharmaceutical Research Services, Houston, Texas 77042, United States
Starting date: March 2005
Ending date: April 2005
Last updated: January 31, 2008